Oracle Runs

Oracle findings and outcome history for Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (NCT06036836).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial completed per input, but no full public readout found on ClinicalTrials.gov or sponsor sites. Cohort A (cSCC) results presented at conference (data cutoff Jun 2025): major clinical benefit 59% (fave/pembro) vs 64% (pembro), pCR ~40% both arms; no added efficacy for favezelimab, higher AEs. Neutral/negative framing for combo vs control; no Cohort B data; incomplete for overall trial readout.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM

Web Searchwslhd.intersearch.com.auNov 7, 2025, 12:00 AM

Coformulation of favezelimab/pembrolizumab neoadjuvant in resectable cSCC: Cohort A KEYFORM-010 results

Major clinical benefit 59% (fave/pembro n=41) vs 64% (pembro n=42); pCR ~40% both; no additional efficacy with fave/pembro; higher TRAEs (73% vs 48%, gr3+ 34% vs 2%). High responses with pembro alone.

ClinicalTrialsclinicaltrials.gov

NCT06036836 Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A-010)

Trial status completed; estimated primary completion Mar 2026; no results posted.

NO_DECISIONDismissed75% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial listed as completed on clinicaltrials.gov (est. prim. compl. Mar 2026; current date Apr 2026) but no posted results or public readout identified for NCT06036836/MK-4280A-010. Cohort A/B abstracts describe design only; later 2025 abstract exists but lacks accessible efficacy interpretation tying clearly to positive/negative framing for this exact trial. Other Merck favezelimab updates concern unrelated Phase 3 failures.

Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:25 PM

Web Searchclinicaltrials.gov

NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab

Current status: Completed. Primary completion: 2026-03-12. No results posted. Endpoints: Clinical Benefit Rate (Cohort A, mPR/pCR or cCR), ORR per RECIST 1.1 (Cohort B).

Web Searchmerck.comDec 16, 2024, 12:00 AM

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs

Merck discontinued favezelimab (MK-4280) development in KEYFORM program after program-wide data review. No mention of MK-4280A-010 Phase 2 readout in cSCC or EC.

Web Searchjitc.bmj.comNov 7, 2025, 12:00 AM

Results from cohort a of the phase 2 keyform-010 study

Abstract on KEYFORM-010 (NCT06036836) Cohort A results for neoadjuvant favezelimab/pembrolizumab in resectable cSCC; no specific efficacy numbers or positive/negative framing accessible in search results.

NO_DECISIONDismissed80% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM

ClinicalTrialsclinicaltrials.govMar 19, 2026, 12:00 AM

Study Details | NCT06036836 | ClinicalTrials.gov

ClinicalTrials.gov lists completed; primary completion 2026-03-12; hasResults=false on the latest posted update.

NO_DECISIONDismissed83% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear overall trial-level readout was found. A 2025 cohort A abstract reported no added efficacy for favezelimab/pembrolizumab vs pembrolizumab and more toxicity, but that is only one cohort. I did not find a public cohort B or full KEYFORM-010 trial interpretation, so the overall Phase 2 outcome remains not clearly classifiable.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM

Web Searchwslhd.intersearch.com.auJan 1, 2025, 12:00 AM

Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma: Results from cohort A of the phase 2 KEYFORM-010 study

Conference abstract for cohort A: major clinical benefit was high in both arms; favezelimab/pembrolizumab had higher adverse events and no additional efficacy over pembrolizumab alone.

Sponsormsd.trialsummaries.com

Study of Favezelimab Coformulated with Pembrolizumab (MK-4280A) in Participants with Selected Solid Tumors (MK-4280A-010)

Sponsor-authorized public trial page for 4280A-010 shows study metadata and protocol materials, but no posted trial results summary or overall efficacy interpretation.

NO_DECISIONDismissed87% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public evidence is incomplete and not clearly framed for the full trial. I found a trial-specific results abstract for Cohort A only, but the available snippet gives no clear positive/negative interpretation, and the protocol shows this Phase 2 basket trial also includes a separate endometrial cancer cohort.

Found Apr 1, 2026, 7:54 PMReviewed Apr 1, 2026, 7:55 PM

Web Searchjitc.bmj.com

1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cSCC: Results from cohort A of the phase 2 KeyForm-010 study

Trial-specific results were reported for Cohort A of KeyForm-010, but the accessible snippet is limited and does not clearly characterize the readout as positive or negative.

Web Searchsciencedirect.comApr 1, 2024, 12:00 AM

A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A vs Pembrolizumab in Resectable cSCC

Protocol abstract identifies MK-4280A-010/NCT06036836 as a basket Phase 2 study and states Cohort A is cSCC within a broader solid-tumor program, supporting that a Cohort A-only abstract is not an overall trial readout.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.